Charles River Laboratories International, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended December 28, 2019 (52 weeks). The filing also presents fourth-quarter results; this is an annual report, not a standalone Q4 filing. Amounts are U.S. dollars.
Business context
Charles River is an early-stage contract research organization serving pharmaceutical, biotechnology, academic and government customers. Its three segments are Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support. DSA represented about 61.8% of FY2019 revenue. The company reported stronger demand across its businesses, particularly from biotechnology clients and in safety assessment, discovery services and manufacturing-support products.
Key financial results
| Metric | FY2019 | FY2018 | Change |
|---|---|---|---|
| Revenue | $2.621 billion | $2.266 billion | +15.7% |
| Service revenue | $2.029 billion | $1.688 billion | +20.2% |
| Product revenue | $591.9 million | $578.2 million | +2.4% |
| Operating income | $351.2 million | $331.4 million | +6.0% |
| Operating margin | 13.4% | 14.6% | Down 1.2 percentage points |
| Net income attributable to common shareholders | $252.0 million | $226.4 million | +11.3% |
| Diluted EPS from continuing operations | $5.07 | $4.59 | +10.5% |
| Cash from operating activities | $480.9 million | $441.1 million | +9.0% |
| Capital expenditures | $140.5 million | $140.1 million | Approximately flat |
Revenue growth reflected acquisitions, higher demand and pricing, partly offset by $36.1 million of unfavorable foreign-exchange effects (about 1.5%). DSA revenue grew 22.9%, Manufacturing 8.3%, and RMS 3.3%. Segment operating margins were 16.0% for DSA, 31.3% for Manufacturing and 24.9% for RMS. Management attributed the consolidated margin decline to acquisition-related amortization and integration costs, restructuring, hiring and wage increases, capacity expansion, and IT and infrastructure investment; volume, mix, pricing and productivity provided offsets.
Q4 FY2019: Revenue was $691.1 million versus $601.5 million a year earlier; operating income was $108.8 million versus $102.5 million; net income attributable to common shareholders was $80.3 million versus $59.7 million; and diluted EPS was $1.61 versus $1.21.
Cash, debt and liquidity
- Cash and cash equivalents were $238.0 million at year-end, up from $195.4 million; short-term investments were $0.9 million.
- Current assets were $1.021 billion and current liabilities $710.2 million.
- Debt and finance lease obligations totaled $1.906 billion before debt discounts and issuance costs; reported long-term debt, net, and finance leases were $1.850 billion. Cash from operations less capital expenditures was approximately $340.4 million.
- The company issued $500 million of 4.25% senior notes due 2028 and used proceeds and cash to prepay $500 million of term loans. Its revolving facility was expanded from $1.55 billion to $2.05 billion; $676.1 million was outstanding at year-end. The company reported compliance with debt covenants.
- Management said existing funds, operating cash generation and access to financing were expected to fund operations for the foreseeable future. A 100-basis-point increase in interest rates was estimated to increase annual pretax interest expense by $8.7 million.
Material changes, outlook and notable items
- Acquisitions materially contributed to growth: Citoxlab was acquired in April 2019 for a preliminary $527.7 million, and a DSA supplier was acquired in August. HemaCare was acquired on January 3, 2020 for approximately $380 million in cash; it is a subsequent event, not part of FY2019 results, and is to be reported in RMS.
- Management described demand and biotechnology funding as robust, reported strong utilization in Safety Assessment, and cited growth opportunities in discovery services, rapid microbial testing and biologics testing. The filing provides no quantified FY2020 revenue or earnings guidance.
- FY2019 income-tax expense was $50.0 million and the effective tax rate was 16.5%, down from 19.3%. The rate benefited from a $20.6 million tax benefit associated with recognition of certain foreign net operating loss deferred tax assets, partly offset by a substantial valuation allowance.
- Restructuring costs were $13.8 million, versus $7.6 million in FY2018. Acquisition and integration activity also increased amortization and expenses. No goodwill impairment was recorded.
- The company identified unauthorized access to portions of its information systems in March 2019, involving copied data that included client information. It reported completing remediation in December 2019 and said the financial impact was not material; potential client, regulatory, litigation and reputational consequences remain risks.
- Other principal risks include reduced client R&D spending or outsourcing, acquisition integration, competition and pricing, foreign-exchange movements, supply interruptions and animal contamination, regulatory or data-integrity failures, cybersecurity, and leverage. The filing specifically discussed pandemic-related supply, donor-availability and operational disruption risks.
- The U.S. Pension Plan termination was in process, with completion and settlement expected in FY2020; the filing estimated approximately $94 million of payments to participants in connection with termination.
Most important facts for investors to verify
- How much reported growth reflects acquired businesses versus underlying demand, pricing and volume, and whether acquisition integration delivers expected returns.
- Whether margins recover as capacity investments, restructuring and integration costs develop, particularly in DSA and RMS.
- Post-year-end borrowing and leverage following the HemaCare acquisition, including remaining revolver availability and covenant headroom.
- Whether the $20.6 million tax benefit and future use of foreign tax-loss carryforwards are sustainable; $294.9 million of the related deferred tax assets was covered by a valuation allowance.
- Any further consequences from the 2019 cybersecurity incident, including client or regulatory actions, and execution of the U.S. pension-plan termination.
- Audit context: the financial statements received an unqualified opinion and internal control over financial reporting was judged effective; the 2019 internal-control assessment excluded Citoxlab and the acquired DSA supplier.